Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

@article{Sampson2010ImmunologicEA,
  title={Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.},
  author={John H. Sampson and Amy Heimberger and Gary E. Archer and Kenneth D. Aldape and Allan H. Friedman and Henry S. Friedman and Mark R. Gilbert and James E. Herndon and Roger E McLendon and Duane A. Mitchell and David A Reardon and Raymond A Sawaya and Robert J. Schmittling and Wei Shi and James J. Vredenburgh and Darell D Bigner},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 31},
  pages={4722-9}
}
PURPOSE Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms. PATIENTS AND METHODS A phase II, multicenter trial was undertaken to assess the immunogenicity of an EGFRvIII-targeted peptide vaccine and to… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS